Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

Key Points

• Jupiter Topco LLC acquired 466,611 Savara shares worth approximately $2.88 million, giving it a 0.23% stake. Institutional investors collectively own 87.93% of the company.
• Savara reported quarterly EPS of negative $0.16, missing the consensus estimate of negative $0.14. Analysts expect a full-year loss of approximately $0.62 per share.
• SVRA recently traded at $5.46, while analysts maintain a consensus “Moderate Buy” rating and a $10.14 target price. Savara is developing Molgradex for the rare lung disease autoimmune pulmonary alveolar proteinosis.

Jupiter Topco LLC purchased a new position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 466,611 shares of the company's stock, valued at approximately $2,875,000. Jupiter Topco LLC owned 0.23% of Savara as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in SVRA. BlackRock Inc. purchased a new position in shares of Savara during the 2nd quarter worth approximately $76,966,000. Polar Capital Holdings Plc purchased a new stake in shares of Savara in the fourth quarter valued at approximately $50,086,000. RTW Investments LP acquired a new position in Savara during the fourth quarter worth $35,893,000. VR Adviser LLC grew its holdings in Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock worth $20,256,000 after acquiring an additional 5,626,624 shares during the period. Finally, Marshall Wace LLP purchased a new position in Savara in the fourth quarter worth $27,496,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Stock Performance

SVRA opened at $5.46 on Thursday. Savara Inc. has a 1-year low of $3.32 and a 1-year high of $7.01. The stock has a market cap of $1.12 billion, a P/E ratio of -9.41 and a beta of 0.25. The stock's 50 day simple moving average is $5.68 and its 200 day simple moving average is $5.48. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, equities analysts anticipate that Savara Inc. will post -0.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.14.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source